Blog Posts
pembrolizumab

Pembrolizumab followed by irreversible electroporation of a liver metastasis in Pancreatic Cancer patients

Anirban Maitra, Professor of Pathology and Translational Molecular Pathology at UT MD Anderson Cancer Center, shared on X:

“Pembrolizumab followed by irreversible electroporation of a liver metastasis in pancreatic cancer patients: iScience

Authors: Rasmus Virenfeldt Flak, Emil Kofod-Olsen, Nikolaj Dich Sølvsten, Gintare Naujokaite, Ralf Agger, Mogens Tornby Stender, Signe Christensen, Susy Shim, Laurids Østergaard Poulsen, Sönke Detlefsen, Ole Thorlasius-Ussing, Morten Ladekar

Pembrolizumab followed by irreversible electroporation of a liver metastasis in Pancreatic Cancer patients

When you combine one ineffective therapy in pancreatic cancer (aPD1) with another (IRE), the cumulative result is still ineffective. Everyone progressed right through it.”

Pembrolizumab followed by irreversible electroporation of a liver metastasis in Pancreatic Cancer patients

Anirban Maitra serves as Professor of Pathology and Translational Molecular Pathology at UT MD Anderson Cancer Center since August 2013, and directs the Sheikh Ahmed Pancreatic Cancer Research Center. He leads an NCI-funded laboratory dedicated to pancreatic cancer research, focusing on genetics and molecular pathology in human and mouse models. His research aims to advance early detection and interception strategies to enhance patient survival rates in pancreatic cancer.

Anirban Maitra cancer Emil Kofod-Olsen Gintare Naujokaite Laurids Østergaard Poulsen Liver metastasis Mogens Tornby Stender Morten Ladekar Nikolaj Dich Sølvsten Ole Thorlasius-Ussing OncoDaily Oncology Pancreatic Cancer Ralf Agger Rasmus Virenfeldt Flak Signe Christensen Sönke Detlefsen Susy Shim